Private Equity
Andea Alms Video: Money In Motion 118 - Antibody Drug Conjugate (ADC) Market
August 2024 - Private Equity
TRANSCRIPT:
Hello, my name is Andrea Alms. I'm a technology investor and financial manager and this is your money in motion. In the news, Merck and company is making a push to dominate small cell lung cancer. In October 2023, Merck paid Daiichi $4 billion to partner on a slate of antibody drug conjugates ADC. Merck paid 800 680 million for Harpic. The original deal between Merck and IHG included a B7, H3 directed ADC that entered phase three.
What is it? Antibody drug conjugates ADCs are monoclonal antibody mAbs engineered mAbs are combined with cytotoxic agents. An ideal ADC has the following features. One. The monoclonal antibody targets a specific cancer antigen. Two while not harming healthy cells, according to the press, the global antibody drug market was 9.04 billion in 2022 and is projected to grow to 25.46 billion by 2032, at a compound average growth rate of 10.91%.
At market and markets, the market size was 9.7 billion in 2023 and expected to grow to 19.8 billion by 2028, growing at 15.2%. At research and markets, the market was 5.9 billion in 2022 and grow to 13.06 billion by 2026 at a growth rate of 22%. Averaging the averages, the market size is 7.5 billion at a 16% compound average growth rate.
Thank you. This is your money. Your money in motion.